

Biosimilars in Medicare Part D

ISSUE: Currently, biosimilar products are excluded from Part D’s coverage-gap discount program. As a result, plan sponsors and beneficiaries may have less incentive to use biosimilars.

KEY POINTS: To encourage the use of biosimilars when clinically appropriate, policymakers may want to how biosimilars are treated under Part D.

ACTION: Commissioners should review the material in preparation for discussions at the November meeting.